<DOC>
	<DOCNO>NCT00397579</DOCNO>
	<brief_summary>RATIONALE : Combinations biological substance DT388IL3 fusion protein may able carry cancer kill substance directly cancer cell . PURPOSE : This phase I/II trial study side effect best dose DT388IL3 fusion protein see well work treat patient acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>DT388IL3 Fusion Protein Treating Patients With Acute Myeloid Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose DT_388IL3 fusion protein patient refractory relapse poor-risk acute myeloid leukemia ( AML ) high-risk myelodysplastic syndrome ( MDS ) . - Define dose-limiting toxicity regimen patient . - Measure pharmacokinetics regimen patient . - Measure immune response patient treat regimen . - Evaluate response correlate disease type ( relapsed/refractory poor-risk de novo AML high-risk MDS ) , pretreatment marrow blast percentage , leukemia blast interleukin-3 receptor density . OUTLINE : This phase I , multicenter , dose-escalation study follow phase II , open-label study . - Phase I : Patients receive DT_388IL3 IV 15 minute daily 5 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos DT_388IL3 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : An additional 15 patient receive DT_388IL3 MTD phase I . Patients undergo serum blast collection periodically laboratory study , include analysis expression interleukin-3 receptor anti-DT_388IL3 antibody baseline . Samples also analyze immunoenzyme assay flow cytometry . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Histologically morphologically confirm acute myeloid leukemia ( AML ) , meet 1 follow criterion : Relapsed refractory AML treatment ≥ 1 prior conventional induction therapy Patients early first relapse must match donor available and/or ineligible allogeneic stem cell transplantation Poorrisk AML , define follow criterion : Treatmentrelated AML , unless associate favorable cytogenetics ( e.g. , inversion 16 , [ 16 ; 16 ] , [ 8 ; 21 ] , [ 15 ; 17 ] ) , ineligible stem cell transplantation Antecedent hematological disease ( e.g. , myelodysplastic syndrome , myelofibrosis , polycythemia vera ) evolve AML ( ≥ 20 % blast ) ineligible stem cell transplantation De novo AML ( must &gt; 70 year age ) AML unfavorable cytogenetics ( e.g. , abnormality chromosomes 7 , 5 , 7q , 5q ; complex [ ≥ 3 ] abnormality ; abnormality 11q23 , exclude [ 9 ; 11 ] , [ 9 ; 22 ] , inversion 3 , [ 3 ; 3 ] , [ 6 ; 9 ] ) , regardless age , ineligible allogeneic stem cell transplantation Highrisk myelodysplastic syndrome diagnose morphologic , histochemical , cell surface marker criterion Resistant intolerant chemotherapy Ineligible unwilling undergo immediate allogeneic stem cell transplantation Bone marrow index ( i.e. , percent cellularity × percent blast ) ≤ 40 % time treatment No active CNS leukemia PATIENT CHARACTERISTICS : ECOG performance status 02 Bilirubin ≤ 1.5 mg/dL ALT AST &lt; 2.5 time upper limit normal Albumin ≥ 3 mg/dL Creatinine ≤ 1.5 mg/dL LVEF ≥ 50 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 week completion study treatment No complicate medical psychiatric problem would preclude study compliance No concurrent serious uncontrolled infection disseminate intravascular coagulation No myocardial infarction within past 6 month No allergy diphtheria toxin No requirement oxygen PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent antineoplastic drug No concurrent radiotherapy No concurrent corticosteroid antiemetic No concurrent hematopoietic growth factor ( e.g. , epoetin alfa , interleukin11 , filgrastim [ GCSF ] , sargramostim [ GMCSF ] ) No concurrent intravenous immunoglobins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>blastic plasmacytoid dendritic cell neoplasm</keyword>
	<keyword>plasmacytoid dendritic cell leukemia</keyword>
	<keyword>CD123+</keyword>
</DOC>